The management of unresectable hepatocellular carcinoma (HCC) involves recognizing and managing adverse events and effectively working with a multidisciplinary team. This Clinical ForumSM brings together an interventional radiologist, oncologist, and hepatologist to discuss how they work together at their institutions to achieve a common goal.
In this CME activity, you will hear insights from 3 hemophilia experts on the current management approach to hemophilia A with and without inhibitors, new developments in hemophilia A therapies, and ways to incorporate shared decision making when treating patients with hemophilia A. In addition, you will have an opportunity to practice through a series of questions and compare yourself to your peers.
This enduring activity will provide learners with the latest developments in immunotherapy for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.
For over a decade, sorafenib was the only systemic agent available for the treatment of advanced hepatocellular carcinoma. However, the past 2.5 years has added 6 additional agents. In this Clinical ForumSM, our multidisciplinary expert roundtable convenes to discuss their collaborative care strategies for first and subsequent line management of advanced hepatocellular carcinoma (HCC) using case-based scenarios.